New US Patent Issued to Immunitor on Oral Vaccine Technology

Share Article

Immune Network Ltd., (IMMFF:PK), reports that the United States Patent and Trademark Office has granted US Patent No. 7,914,799 for composition and methods relating to the platform technology of its main business.

Issued patent reinforces the premises of an earlier patent No. 7,827,099 received in November of last year. "We concur with the USPTO that the subject matter covered by this patent is unique and worthy of patent protection" said Dr. Aldar Bourinbaiar, co-founder of Immunitor and thirty year veteran in the vaccine industry. The newly issued patent deals with oral anti-fungal vaccine.

Pathogenic fungi occur worldwide and can cause diseases in humans, animals and plants. Clinical manifestations from superficial, i.e., skin surface like ringworm or athlete's foot to deeply invasive, disseminated infection, which can be fatal. The life-threatening fungal infections are a growing problem for people with viral infections, such as herpes or HIV, for cancer patients, and for transplant patients. Fungal infections are common and prevalence can be as high as 85% among individuals with AIDS. The incidence of systemic fungal infections increased drastically in recent years, nearly 40% of all deaths from hospital-acquired infections were due to fungi.

The treatment of fungal infections has lagged behind bacterial chemotherapy. There are substantially fewer antifungal drugs than microbial antibiotics. Inadequate spectrum of activity, lack of efficacy due to growing resistance, poor safety profile, multiple drug interactions, inadequate pharmacokinetic profile, and excessive cost have imposed limitations to current therapeutic options. Development of antifungal agents is a challenge because there are few drug targets unique to fungi. The alternative strategy is development of a vaccine, both preventive and therapeutic.

Today, only two fungal vaccines are available. These are veterinary vaccines that are delivered by an injection to prevent ringworm in cattle. No orally delivered fungal vaccines exist at the present time. It is commonly held that when vaccine is given orally the biological activity of such a vaccine is reduced by digestive degradation in the stomach. Scientists have been trying for decades to obviate this problem by developing various means to prevent vaccine degradation. However, this effort has been lengthy and complex and has not borne any fruit. This notion applies not only to fungal vaccine but to other vaccines in general. The issued patent stands out in the crowd since it discloses clinically validated fungal vaccine taken as a simple pill. The patented technology platform of Immunitor as applied to vaccines and immunotherapy now covers fungal infections. Prior issued and pending Immunitor patents cover vaccines against HIV, hepatitis, influenza, tuberculosis, cancer and atherosclerosis.

Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

CONTACT: Immune Network Ltd
IMMFF at yahoo.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aldar Bourinbaiar
Immunitor
1(301) 474-0930
Email >